Platelets in migraine

Abstract Modification in platelet activation and aggregation has been demonstrated in migraine patients both during and between attacks. A different pattern in the secretion of platelet products has also been observed in patients affected by migraine compared with controls. The most important variation concerns a hyposcretion of dense body products. Platelets share structural and functional analogies with monoaminergic neurons, in particular serotoninergic neurons, and have been used as a peripheral model to study monoaminergic function in migraine patients. A reduced turnover of serotonin has been shown in migraine patients in the interictal period, whereas a reduced content of this monoamine was detected in patients with chronic daily headache (CDH), particularly in those with analgesic abuse. Nitric oxide metabolism was also studied in platelets of migraine patients between and during attacks. An increased activity of nitric oxide synthase (NOS), which was more accentuated during attacks, was found in these patients compared to healthy individuals. The increase in platelet NOS activity was also confirmed in CDH patients in association with a reduction of serotonin content and increased calcium levels. Variations in aggregation to different agents and secretion may not, at the moment, be indicative of similar changes in cerebral circulation of migraine patients. Its occurrence should be confirmed in samples of jugular venous blood during attacks to establish a definite link with migraine pathogenesis. Moreover changes in serotonin and NO metabolism observed in platelets of migraine patients may only indirectly suggest similar modifications in the neuronal pathways involved in inducing and maintaining head pain in migraineurs.

Key words Platelets • Aggregation • Secretion • Serotonin metabolism • NO metabolism • Platelet enzymes • Migraine
synthesized from arachidonic acid, induce the secondary, irreversible aggregation of platelets which underlies thrombus formation. These events occur when the vessel wall is damaged, also in the cerebral circulation. One of the first pathogenetic hypotheses formulated for migraine stated that an alteration of platelet function contributed to vascular changes observed during attacks. These changes can also be investigated in the peripheral blood and involve some aspects of platelet function, such as reactivity and aggregability to stimulating agents, secretion from dense bodies and α-granules, as well as microaggregate formation.

Platelet activation and aggregation in migraine

Although certain alterations in platelet function and secretion have been found in migraine patients, their role in the pathogenetic events of a migraine attack remains to be established. The extreme discrepancies among data in this regard should be mentioned. It is mandatory, more than in other cellular models, to define the variability of the tests used in the experimental setting. Some of the main findings on platelet activation and aggregation between attacks are reported in Table 1 [1–7].

Platelet function is influenced by several factors, such as age, sex and stress; stress in particular is believed to be a precipitating factor of migraine attacks. Biochemical modifications found during stressful conditions, such as the increase in catecholamines and free fatty acids in blood, may in fact trigger the activation of platelets.

Taking these considerations into account, the most constant finding in migraine which is more evident during attacks is the increased aggregability of platelets, both spontaneously and subsequent to stimulation by aggregating agents, such as epinephrine, adenosine diphosphate and thrombin. Accordingly, drugs which reduce platelet aggregability, in particular non-steroidal anti-inflammatory drugs, 5HT2 antagonists and beta-blockers, have been proposed for migraine prophylaxis.

However, a recent study by Joseph [8] using impedimetry on whole blood, which more faithfully explores platelet function in vivo, did not show significant variations in migraine patients outside attacks. The same author used the combined results of different tests exploring platelet function (e.g. adhesion, aggregation, secretion, plasma thromboxane levels and circulating microaggregates) to investigate the role of platelets during attacks. He found an increase in the index of platelet function only at the end of attacks, and challenged the hypothesis of platelet intervention as a primum movens of migraine attack [8].

Monamine metabolism in migraine: focus on serotonin

Platelets are structurally and functionally similar to monoaminergic neurons, in particular serotoninergic neurons. The two cell types have a common ectodermic origin. They use Ca2+, intracellular phosphoinositol and prostaglandin pathways for secretion. They bind 5-hydroxytryptamine (5HT2) and imipramine, and metabolize serotonin in a similar manner.

The majority of blood serotonin is localized in platelet dense bodies and is released from platelets after activation. There is a reduced turnover of this monoamine between attacks while it is released during migraine crises. The latter finding was supported by early studies which demonstrated

| Reference       | Year | Patients  | Results                                                                 |
|-----------------|------|-----------|--------------------------------------------------------------------------|
| Hedman et al. [1] | 1988 | MA        | Decreased beta-adrenoreceptor response to stimulation with isoprenaline   |
| Herman et al. [2] | 1989 | MA and MwA | Decreased sensitivity of platelets to PAF                                 |
| Takeshima et al. [3] | 1989 | Migraine, type not specified | Increased activation during cold pressure test                             |
| Kovacs et al. [4]  | 1990 | MA        | Increased activation to ADP and PAF                                       |
| D’Andrea et al. [5] | 1994 | MA and MwA | Decreased collagen-induced aggregation                                   |
| Kitano et al [6] | 1994 | MA and MwA | Continuous activation measured as increased values of 11-dehydrothromboxane B2 |
| Tozzi et al. [7]  | 1996 | MA and MwA | Perturbed platelet viscosity; Decreased stimulation-induced influx of external calcium through the platelet membrane; Hyperaggregation to adenosine diphosphate and collagen |

MA, migraine with aura; MwA, migraine without aura; PAF, platelet-activating factor
a reduced platelet content of serotonin that was attributed to an unidentified plasma releasing factor. The principal data on serotonin metabolism in migraine outside the attacks are summarized in Table 2 [9–17].

Differences in platelet serotonin content have been observed between migraine with aura and migraine without aura patients assessed between attacks [15]. Changes in serotonin content were also noticed in women with menstrual migraine, in relation to the cyclic hormonal variations. In these women, platelet serotonin levels peaked in the follicular period and decreased in the luteal phase, when 5HIAA values were particularly increased [16, 17]. These data suggest an aberration in menstrual cycle-related changes of serotonin in women migraineurs, possibly due to increased catabolism or reduced synthesis which predisposes these patients to migraine attacks.

The decreased secretion from platelet dense bodies in migraine was suggested by the finding of higher norepinephrine content [18]. This observation, together with adenosine triphosphate (ATP) hypossecretion, is evidence of sympathetic hypofunction in migraine.

The defective turnover of platelet serotonin between attacks may reflect a hyposerotoninergic status at the central level. This hyposertoninergic status is more accentuated in chronic daily headache, in particular when associated with analgesic abuse, as demonstrated by several recent studies [19–21].

Alterations in serotonin metabolism and turnover are reflected by the different patterns of expression of 5HT2 receptors. In migraine patients, particularly in those with aura, a down-regulation of these receptors was observed even in headache-free period, whereas in transformed migraine the most relevant finding was an up-regulation of the same receptors. These observations support the hypothesis of a derangement of the serotonin system related to the chronicization of headache in these patients [22, 23].

**Other neurotransmitters in platelets of migraine patients**

Variations in the levels of other neurotransmitters in platelets of migraine patients have also been observed. The most suggestive finding is the higher values of glutamate in platelets of migraine patients compared with controls, implicating an analogous alteration in the central nervous system. Increased platelet glutamate may underlie the NMDA-mediated events hypothesized to be involved in the aura pathogenesis [24, 25].

Elevated values of substance P were found in platelets of migraine patients during attacks, as were reduced levels of 5-HT; a negative correlation between the two neurotransmitters was noted. In migraine patients an uptake of substance P, released by trigeminal nerves, may explain

### Table 2 Serotonin metabolism in platelets from migraine subjects, during headache-free periods

| Authors           | Year | Patients          | Results                                                                 |
|-------------------|------|-------------------|-------------------------------------------------------------------------|
| D’Andrea et al. [9] | 1987 | MA and MwA        | Decreased 5HT turnover                                                  |
| D’Andrea et al. [10] | 1989 | MA                | Increase in the content of serotonin, not evident in MA Decrease in 5-HIAA (also in MwA) |
| D’Andrea et al. [11] | 1989 | MA and MwA        | High NE levels and low 5-HT/NE ratio in platelets of patients with MwA; High 5-HT levels and high 5HT/NE ratio in platelet of patients with MA |
| Joseph et al. [12], 1989 | Migraine patients (migraine form is not specified) | Increased number of dense bodies; Altered coupling of 5HT secretion from dense bodies and ionised calcium; Decreased serotonin secretion |
| Riddle et al. [13] | 1989 | MA and MwA        | Increase in the number of dense bodies                                  |
| Joseph et al. [14] | 1989 | MA and MwA        | Abnormal sensitivity to PAF                                              |
| D’Andrea et al. [15] | 1994 | MA                | Increased basal platelet 5HT and increased 5HT secretion induced by both collagen and PAF (not evident in MwA) |
| D’Andrea et al. [16] | 1995 | MM, TTH and controls | Plasma and platelet 5HT peak in MM in ovulatory phase; 5HT peak evident in follicular phase in TTH and controls |
| Fioroni et al. [17] | 1996 | MM                | Reduced 5HT and increased 5HIAA in luteal phase, suggesting a greater susceptibility to attacks in this period |

MA, migraine with aura; MwA, migraine without aura; 5HT, serotonin; NE, norepinephrine; PAF, platelet-activating factor; MM, menstrual migraine; TTH, tension-type headache; 5HIAA, 5-hydroxyindolacetic acid
the increase of this neuropeptide in platelets. Substance P may contribute to trigger attacks by releasing 5-HT by platelets [26].

Another suggestive finding in migraine was the increased metenkephalin secretion from platelets during attacks, which has been interpreted as a compensatory mechanism antagonizing the serotonin release from platelets occurring ictally [27].

**Platelets as a model for the study of NO metabolism**

Platelets possess a constitutive form of nitric oxide synthase (NOS) which intervenes in the formation of NO from l-arginine [28]. The most specific agent able to activate NOS in platelets is collagen [29].

Our group found an increase in platelet NOS activity, both basal and collagen-stimulated, in migraine patients assessed between attacks [30]. This was accompanied by a significant rise in the intracellular messenger cyclic guanosine monophosphate (cGMP) [30]. This increase may account for some alterations in platelet function observed in migraineurs, such as the increase in platelet content of cyclic guanosine monophosphate (cGMP) [30]. This increase may contribute to trigger attacks by releasing 5-HT by platelets [26].

The most specific agent able to activate NOS in platelets is collagen [29].

Our group also found an increased activity in the L-arginine pathway of platelets, especially during attacks, by demonstrating increased NO end-products compared with headache-free period [31].

The significance of the previously described changes to migraine pathogenesis remains to be established. The increase in NO formation may represent a mechanism to compensate for the aggregation induced by unknown factors, and therefore may be a short-acting feedback mechanism in peripheral and also cerebral circulation. On the other hand, the increase in NO synthase activity of platelets, which is present also in headache-free periods, could reflect a more generalized increase in NO synthesis, as suggested by Olesen et al. [32], who considered this messenger the "key molecule" of migraine.

Our group also found an increased activity in the L-arginine/NO pathway in the late luteal phase in women with menstrual migraine. This increase, together with neurotransmitter modifications and hormonal changes, may account for the greater susceptibility to attacks in the perimenstrual period [33].

The significant increase in NOS activity in patients with chronic daily headache, associated with reduced serotonin levels, suggests the failure of this pathway to antagonize the increase in cytosolic calcium [21]. This leads to the depletion of serotonin in the platelet dense bodies.

Considering platelets as a peripheral model of serotoninergic neurons, an analogous depletion at the central level may contribute to maintain attacks and lead to the chronicization of head pain [34]. As stated before, serotoninergic hypofunction could be accentuated by analgesic abuse.

**Platelet enzymes in migraine**

The first research carried out in platelets concerned the enzymes monoamine oxidase (MAO), present in platelets mainly in the B isoform which uses tyramine and tryptamine as substrates, and the enzyme phenol sulphatase, whose substrate is unknown. These studies found an altered activity of both enzymes, particularly in patients who reported certain foods as trigger factors [35–39].

The alteration of MAO-B activity in platelets was reported particularly during migraine attacks, and was more accentuated in women with migraine related to menstrual cycle; this change is not specific for migraine as it was also found in patients with tension-type headache [16].

An analogous alteration in the activity of phenol sulphotransferase has been hypothesized to promote the absorption of toxic substances by intestinal tract and to trigger migraine attacks, at least in a subgroup of migraine patients [37, 38].

A defect of superoxide dismutase has also been observed in migraine [40] and suggests that patients with migraine (with or without aura) are vulnerable to oxidative stress. The role of the impairment of this radical-scavenging enzyme remains to be established [40].

**Secretion products from platelets in migraine**

Studies on the secretion products of platelets from migraine patients have given contrasting results. One showed an increased platelet adenosine content compared with control subjects, in agreement with the finding of a reduced adenosine release from dense bodies accompanied by the activation of A2 receptors [41]. The inhibited adenosine release may participate in the rapid elimination of serotonin in migraine sufferers [41]. An increase in β-thromboglobulin, a 35 000 dalton protein, released from α-granules as a consequence of platelet activation has also been observed during migraine [15]. This increased secretion was accompanied by a similar increase in thromboxan and prostacyclin, evidence of a more generalized platelet activation [42].

A different behavior of platelet factor 4 (PF4) secretion induced by collagen was observed in migraine with and without aura patients. Platelets of the former patients exhibited a reduced secretion, not observed in the latter. The
reduced PF4 secretion was coupled with an increased basal intraplatelet serotonin concentration and secretion induced by collagen, suggestive of a different serotonin turnover in this migraine subtype. However, a similar trend in PF4 secretion induced by PAF was observed in the two migraine forms, but in migraine with aura patients the increased secretion observed was greater than that found in migraine without aura patients, reflecting an abnormal α-granule secretion [15].

Conclusions

Although data on platelets in migraine are contrasting and inconclusive, some important concepts can be derived from studies carried out in this regard. The findings of platelet dysfunctioning, as well as alterations in neurotransmitter content and secretion, all refer to the peripheral circulation. The alterations detected, in particular those concerning serotonin, are nonetheless suggestive of analogous functional abnormalities in central pathways involved in head pain in migraine, given the analogies between platelets and monoaminergic neurons.

Variations in platelet aggregation and secretion to different agents cannot, at the moment, be assumed as indicative of similar changes in cerebral circulation in migraine. Experimental evidence from the neurogenic inflammation model suggests an activation of platelets, but this finding should be confirmed in samples of jugular blood of migraine patients assessed during attacks.

The role of PAF, considered by some authors to be pivotal in the pathogenetic events involved in migraine attack, should be confirmed, especially because of the extreme difficulty in quantifying it. Even for PAF, conclusive information should be derived from samples of jugular blood of migraine patients taken during the crises, when a reliable test for detecting this factor becomes available.

References

1. Hedman C, Winther K, Knudsen JB (1988) Platelet function in classic migraine during attack-free periods. Acta Neurol Scand 78(4):271–277
2. Herman F, Magyar K, Kovacs K, Filep J (1989) Decreased sensitivity of platelets to platelet-activating factor in migraine patients during the headache-free interval. Thromb Haemost 62(2):818
3. Takeshima T, Takao Y, Urakami K, Nishikawa S, Takahashi S (1989) Muscle contraction headache and migraine. Platelet activation and plasma norepinephrine during the cold pressor test. Cephalalgia 9(1):7–13
4. Kovacs K, Herman F, Filep J, Jelencsik I, Magyar K, Csanda E (1990) Platelet aggregation of migraineurs during and between attacks. Cephalalgia 10(4):161–165
5. D’Andrea G, Cananzi AR, Perini F, Alecci M, Zamberlan F, Hasselmark L, Welch KM (1994) Decreased collagen-induced platelet aggregation and increased platelet arginine levels in migraine: a possible link with the NO pathway. Cephalalgia 14(5):352–356
6. Kitano A, Shimomura T, Takeshima T, Takahashi K (1994) Increased 11-dihydrothromboxane B2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache 34(9):515–518
7. Tozzi E, Tozzi-Ciancarelli MG, Di Massimo C, Mascoli A, Angelini R, de Matteis F (1996) Platelet responsiveness in migrainous children during headache-free period. Headache 36(2):95–99
8. Joseph R (1991) The platelet theory of migraine: a controlled clinical and laboratory evaluation. M. Phil. Thesis, Faculty of Medicine, University of London, London
9. D’Andrea G, Welch KM, Levine SR, Nagel-Leiby S, Joseph R (1987) Reduced platelet turnover of serotonin in diet restricted migraine patients. Cephalalgia 7[Suppl 6]:141–143
10. D’Andrea G, Welch KM, Riddle JM, Grunfeld S, Levine SR, Nagel-Leiby S, Joseph R (1989) Platelet serotonin and ultrastructure in migraine. Arch Neurol 46(11):1187–1189
11. D’Andrea G, Welch KM, Grunfeld S, Joseph R, Nagel-Leiby S (1989) Platelet norepinephrine and serotonin balance in migraine. Headache 29(10):657–659
12. Joseph R, Welch KM, D’Andrea G, Welch KM, Joseph R, McElroy HH, Grunfeld S, Christopherson TG (1989) Platelet activation and analysis of organelles in migraineurs. Headache 29(1):28–33
13. Joseph R, Welch KM, Grunfeld S, Oster SB, D’Andrea G (1988) Cytosolic ionized calcium homeostasis in platelets: an abnormal sensitivity to PAF-activation in migraine. Headache 28(6):396–402
14. D’Andrea G, Hasselmark L, Alecci M, Cananzi A, Perini F, Welch KM (1994) Platelet secretion from dense and alpha-granules in vitro in migraine with or without aura. J Neurol Neurosurg Psychiatry 57(5):557–561
15. D’Andrea G, Hasselmark L, Cananzi AR, Alecci, M, Perini F, Zamberlan F, Welch KM (1995) Metabolism and menstrual cycle rhythmicity of serotonin in primary headaches. Headache 35(4):216–221
16. Fioroni L, Andrea GD, Alecci M, Cananzi A, Facchinetti F (1996) Platelet serotonin pathway in menstrual migraine. Cephalalgia 16(6):427–430
17. Joseph R, Welch KM, D’Andrea G, Levine SR (1986) ATP hyposecretion from platelet dense bodies - evidence for the purinergic hypothesis and a marker of migraine. Headache 26(8):403–410
19. Srikiatkhachorn A, Maneesri S, Govitrapong P, Kasanotikul V (1998) Derangement of serotonin system in migrainous patients with analgesic abuse headache: clues from platelets. Headache 38(1):43–49

20. Srikiatkhachorn A, Tarasub N, Govitrapong P (2000) Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 40(5):343–350

21. Sarchielli P, Alberti A, Russo S, Codini M, Panico R, Floridi A, Gallai V (1999) Nitric oxide pathway, Ca²⁺, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 19:810–816

22. Ribeiro CA, Cotrim MD, Morgadinho MT, Ramos MI, Santos ES, De Macedo TD (1990) Migraine, serum serotonin and platelet 5-HT2 receptors. Cephalalgia 10(5):213–219

23. Srikiatkhachorn A, Govitrapong P, Limthavon C (1994) Up-regulation of 5-HT2 serotonin receptor: a possible mechanism of transformed migraine. Headache 34(1):8–11

24. Cananzi AR, D’Andrea G, Perini F, Zamberlan F, Welch KM (1995) Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia 15(2):132–135

25. D’Andrea G, Cananzi AR, Perini F, Hasselmark L (1995) Platelet models and their possible usefulness in the study of migraine pathogenesis. Cephalalgia 15:265–271

26. Gallai V, Floridi A, Mazzotta G, Codini M, Tognoloni M, Vulcano MR, Sartori M, Russo S, Alberti A, Michele F, Sarchielli P (1996) l-Arginine/nitric oxide pathway activation in platelets of migraine patients with and without aura. Acta Neurol Scand 94(2):151–160

27. Ferrari MD, Odink J, Frolich M, Tapparelle C, Portielje JE (1989) Release of platelet Met-enkephalin, but not serotonin, in migraine. A platelet response unique to migraine patients? J Neurol Sci 93(1):51–60

28. Radomski MW, Palmer RMJ, Moncada S (1990) L-Arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 87:5193–5197

29. Ferrari MD, Odink J, Frolich M, Tapparelle C, Portielje JE (1989) Release of platelet Met-enkephalin, but not serotonin, in migraine. A platelet response unique to migraine patients? J Neurol Sci 93(1):51–60

30. Olesen J, Thomsen LL, Iversen HK (1994) Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 15:149–153

31. Marazziti D, Bonuccelli U, Nati A, Toni C, Pedri S, Palego L, Pavese N, Lucetti C, Muratorio A, Cassano GB (1994) Platelet 3H-imipramine binding and sulphotransferase activity in primary headache. Cephalalgia 14(3):210–214

32. Shimomura T, Kowa H, Nakano T, Kitano A, Marukawa H, Urakami K, Takahashi K (1994) Platelet superoxide dismutase activity in blood platelets of migraine patients. J Neurol Transm Suppl 32:161–164

33. Launay JM, Soliman H, Pradalier A, Dry J, Dreux C (1988) Platelet phenol sulphotransferase activities: a migraine marker? Theraphie 43(4):273–27 (in French)

34. Marazziti D, Bonuccelli U, Nati A, Toni C, Pedri S, Palego L, Pavese N, Lucetti C, Muratorio A, Cassano GB (1994) Platelet 3H-imipramine binding and sulphotransferase activity in primary headache. Cephalalgia 14(3):210–214

35. Kovacs K, Jenecsiik I, Csanda E, Magyar K (1990) Changes in monoamine oxidase (MAO) activity in migraine. Acta Physiol Hung 75[Suppl]:181–182

36. Mosnaim AD, Huprikar S, Wolf ME, Diamond S (1990) Platelet monoamine oxidase activity in female migraine patients. Headache 30(8):488–490

37. Caramona MM, Cotrim MD, Ribeiro CF, Macedo T (1990) Monoamine oxidase activity in blood platelets of migraine patients. J Neurol Transm Suppl 32:161–164

38. Mezei Z, Kis B, Gecse A, Tajti J, Boda B, Telegdy G, Vecsei L (2000) Platelet arachidonate cascade of migraineurs in the interictal phase. Platelets 11(4):222–225